Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cyclophosphamide for Refractory MS
NCT00296205Phase 2Withdrawn
- Sponsor
- Stony Brook University
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in multiple sclerosis (MS), sponsored by Stony Brook University. Planned start Oct 2003; status: withdrawn.
02
Drugs
cyclophosphamide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00296205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296205.